Company news
Alumis Inc. news in 2024
Alumis Inc.'s news releases, calls and decks from 2024, newest first.
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
December 18, 2024
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
November 13, 2024
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
November 12, 2024
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
November 3, 2024
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
September 26, 2024
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
August 12, 2024
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
July 28, 2024
Decks in 2024
- European Academy of Dermatology and Venereology (EADV) Congress 2024
Conference · 12 slides · September 2024
- Technical Presentation (September 2024)
Technical · 14 slides · September 2024
- ESOPRS 2024
Conference · 14 slides · September 2024
- Technical Presentation (May 2024)
Technical · 14 slides · May 31, 2024
- Technical Presentation (March 2024)
Technical · 16 slides · March 2024